Mochida, JP3922800002

Mochida stock: Mochida reports 57,400-share buyback for Mochida stock

Published on 10/24/2026 at 01:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
First-quarter revenue reached JPY 31.72 billion, up 19.10 percent year over year. Mochida stock stood at JPY 3,285.00 on October 23, 2026 after JPY 3,265.00.

Capital return and earnings dates

  • Mochida acquired 57,400 shares during September 2026 under its buyback program announced on October 1, 2026.
  • First-quarter revenue reached JPY 31.72 billion, up 19.10 percent year over year, with net income of JPY 3.18 billion.
  • Mochida stock was last at JPY 3,285.00 on October 23, 2026 at 3:30 p.m. JST on the Tokyo Stock Exchange.
  • The next earnings report is scheduled for October 30, 2026, while the buyback period runs through December 18, 2026.
Mochida, JP3922800002, Illustration mit AI erstellt.

Mochida Pharmaceutical (JP3922800002) acquired 57,400 common shares during September 2026 for JPY 186.62 million. Japan IR reported the transaction on October 1, 2026, giving investors a fresh measure of the company's capital-return program.

Buyback progress reaches 325,900 shares

The September purchase brought cumulative acquisitions to 325,900 shares and JPY 1.05 billion as of September 30, 2026. The board had authorized up to 530,000 shares and JPY 2.00 billion on March 30, 2026, so the cumulative share count represents 61.49 percent of the approved volume.

The chronology shows the program's progression. On March 30, 2026, the board set the 530,000-share ceiling and JPY 2.00 billion limit; on August 3, 2026, Mochida reported first-quarter revenue of JPY 31.72 billion and net income of JPY 3.18 billion; on October 1, 2026, the company disclosed the 57,400-share September purchase. The first-quarter figures and period comparison were carried by Investing.com.

What does the buyback mean for capital returns?

The arithmetic points to a program that had used JPY 1.05 billion of its JPY 2.00 billion authorization by September 30, 2026. The remaining authorization was JPY 945.10 million, while the remaining share capacity was 204,100 shares. Those figures describe execution against the approved limits rather than a forecast of further purchases.

Results date sets the next checkpoint

TradingView lists October 30, 2026 as Mochida's next earnings date. The buyback authorization itself runs through December 18, 2026, according to the October 1 disclosure, leaving two dated reference points for assessing the next capital-return update and the next operating report.

Tokyo quote remains the market reference

Mochida's last reported Tokyo price was JPY 3,285.00 on October 23, 2026 at 3:30 p.m. JST, with a market capitalization of JPY 116.1 billion and a 52-week range of JPY 2,929.00 to JPY 3,965.00. The quote was 17.15 percent below the 52-week high, calculated from the same Tokyo-listed instrument.

The further course of trading is shown by the continuously updated real-time quote of Mochida stock.

Mochida stock key facts

  • Company: Mochida Pharmaceutical Co., Ltd.
  • ISIN: JP3922800002
  • Ticker: 4534
  • Primary exchange: Tokyo Stock Exchange
  • Tokyo price (as of October 23, 2026, 3:30 p.m. JST): JPY 3,285.00
  • Market capitalization: JPY 116.1 billion (as of October 23, 2026)
  • 52-week range: JPY 2,929.00-3,965.00 (as of October 23, 2026)
  • Sector / Industry: Health Care / Pharmaceuticals
  • Next earnings date: October 30, 2026

Market context: Market report Nikkei 225.

More news and analyses on Mochida stock

Disclaimer...
en | JP3922800002 | MOCHIDA | boerse | 70401333 | bgmi